Recipharm AB announced on 4 February 2020 that the offer to acquire Consort Medical plc (Consort) (the Offer) had become unconditional in all respects and will remain open for acceptances for a further 14 days, until 18 February 2020. On February 3, 2020, a new Board of Consort was appointed with Thomas Eldered as Chairman. On 4 February 2020, Recipharms EVP Corporate Development, Mark Quick, in addition to his current position, has been appointed as the new CEO to lead the Consort business through the transition and integration process.